CoChat
Sign Up
Cited by 78

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study

Garcia-Manero, Guillermo, Abaza, Yasmin, Takahashi, Koichi, Medeiros, Bruno C., Arellano, Martha, Khaled, Samer K., Patnaik, Mrinal, Odenike, Olatoyosi, Sayar, Hamid, Tummala, Mohan, Patel, Prapti, Maness-Harris, Lori, Stuart, Robert, Traer, Elie, Karamlou, Kasra, Yacoub, Abdulraheem, Ghalie, Richard, Giorgino, Ruben, Atallah, Ehab·2019·Blood Advances
DOI 10.1182/bloodadvances.2018027409
Open this paper in CoChat — free account

Abstract

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined with azacitidine. This single-group, multicenter phase 2 study assessed the safety and efficacy of pracinostat combined with azacitidine in patients who were at least 65 years old with newly diagnosed AML and who were ineligible for standard induction chemotherapy. Patients received pracinostat 60 mg/d, 3 d/wk, for 3 consecutive weeks, plus azacitidine 75 mg/m2 daily for 7 days in a 28-day cycle. Primary endpoints were complete remission (CR), CR with incomplete count recovery (CRi), and morphologic leukemia-free state (MLFS) rates of the combination. Secondary endpoints included safety, progression-free survival (PFS), and overall survival (OS) of the regimen. Fifty patients (33 de novo, 12 secondary, and 5 therapy-related AML) were enrolled. Twenty-six patients (52%) achieved the primary endpoint of CR (42%), CRi (4%), and MLFS (6%). Median OS and PFS were 19.1 months (95% confidence interval [CI], 10-26.5 months) and 12.6 months (95% CI, 10-17.7 months), respectively, with a 1-year OS rate of 62%. Forty-three patients (86%) experienced at least 1 grade 3 or worse treatment-emergent adverse event with the combination, with infections (52%), thrombocytopenia (46%), and febrile neutropenia (44%) reported as the most common toxicities. The 30- and 60-day all-cause mortality rates were 2% and 10%, respectively. DNA sequencing revealed somatic mutations at baseline, and clearance rates correlated with response to treatment. Pracinostat plus azacitidine is a well-tolerated and active regimen in the frontline treatment of older patients with AML unfit for intensive therapy. A larger controlled trial is ongoing. This trial was registered at www.clinicaltrials.gov as #NCT01912274.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/bloodadvances.2018027409

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Landscape of high-confidence somatic mutations detected in pretreatment BM samples. (A) Number of mutations in each patient by cytogenetic risk group and type of AML. (B) Frequency of each type of mutation by patient. Each column represents 1 patient and each row represents 1 specific mutation.
Figure 1 Landscape of high-confidence somatic mutations detected in pretreatment BM samples. (A) Number of mutations in each patient by cytogenetic risk group and type of AML. (B) Frequency of each type of mutation by patient. Each column represents 1 patient and each row represents 1 specific mutation.CC-BY-NC-ND · From the PDF
Figure 2 Outcomes of patients treated with pracinostat plus azacitidine. (A) OS for the whole cohort. (B) PFS for the whole population. (C) OS stratified by response. The plot shows how the effect of analyzing CR (as a baseline covariate) produces artificial difference; the difference between the overall curve and the curve obtained by censoring at time of CR gives a more realistic view. (D) OS stratified by cytogenetic risk group.
Figure 2 Outcomes of patients treated with pracinostat plus azacitidine. (A) OS for the whole cohort. (B) PFS for the whole population. (C) OS stratified by response. The plot shows how the effect of analyzing CR (as a baseline covariate) produces artificial difference; the difference between the overall curve and the curve obtained by censoring at time of CR gives a more realistic view. (D) OS stratified by cytogenetic risk group.CC-BY-NC-ND · From the PDF
Figure 3 Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status. (A) OS stratified by age. (B) OS stratified by AML subtype. (C) OS stratified by ECOG status.
Figure 3 Outcomes of patients treated with pracinostat plus azacitidine based on age, AML subtype, and ECOG status. (A) OS stratified by age. (B) OS stratified by AML subtype. (C) OS stratified by ECOG status.CC-BY-NC-ND · From the PDF
Figure 4 Representative cases of longitudinal sequencing analyses. Each panel shows data for 1 patient. (A) Prolonged exposure to pracinostat plus azacitidine continued to lower mutants ' VAF. (B) Reexpansion of the original mutations on relapse after achieving CR. (C) Acquisition of a new mutation ( RAD21 ) at the time of relapse with increase of original mutants ' VAF at the time of cycle 6 before frank relapse.
Figure 4 Representative cases of longitudinal sequencing analyses. Each panel shows data for 1 patient. (A) Prolonged exposure to pracinostat plus azacitidine continued to lower mutants ' VAF. (B) Reexpansion of the original mutations on relapse after achieving CR. (C) Acquisition of a new mutation ( RAD21 ) at the time of relapse with increase of original mutants ' VAF at the time of cycle 6 before frank relapse.CC-BY-NC-ND · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. O’Donnell, 2017, Acute myeloid leukemia, version 3.2017, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc Netw, 15, 926, 10.6004/jnccn.2017.0116 · DOI
  2. Kantarjian, 2010, Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia, Blood, 116, 4422, 10.1182/blood-2010-03-276485 · DOI
  3. Anderson, 2002, Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study, Blood, 100, 3869, 10.1182/blood-2001-12-0354 · DOI
  4. Dombret, 2008, Acute myeloid leukemia in the elderly, Semin Oncol, 35, 430, 10.1053/j.seminoncol.2008.04.013 · DOI
  5. Gardin, 2007, Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial, Blood, 109, 5129, 10.1182/blood-2007-02-069666 · DOI
  6. Döhner, 2015, Acute myeloid leukemia, N Engl J Med, 373, 1136, 10.1056/NEJMra1406184 · DOI
  7. Dombret, 2015, International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts, Blood, 126, 291, 10.1182/blood-2015-01-621664 · DOI · Paper page
  8. Fenaux, 2010, Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia, J Clin Oncol, 28, 562, 10.1200/JCO.2009.23.8329 · DOI · Paper page
  9. Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J Clin Oncol, 30, 2670, 10.1200/JCO.2011.38.9429 · DOI
  10. Oran, 2012, Survival for older patients with acute myeloid leukemia: a population-based study, Haematologica, 97, 1916, 10.3324/haematol.2012.066100 · DOI
  11. Granfeldt Østgård, 2015, Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study, J Clin Oncol, 33, 3641, 10.1200/JCO.2014.60.0890 · DOI
  12. Schneider-Stock, 2007, Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors, IDrugs, 10, 557
  13. Cai, 2015, Discovery, bioactivity and docking simulation of vorinostat analogues containing 1,2,4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents, Bioorg Med Chem, 23, 3457, 10.1016/j.bmc.2015.04.028 · DOI
  14. Cameron, 1999, Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer, Nat Genet, 21, 103, 10.1038/5047 · DOI
  15. Yang, 2005, Antileukemia activity of the combination of 5-aza-2′-deoxycytidine with valproic acid, Leuk Res, 29, 739, 10.1016/j.leukres.2004.11.022 · DOI
  16. Kirschbaum, 2014, A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome, Br J Haematol, 167, 185, 10.1111/bjh.13016 · DOI
  17. Gore, 2006, Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms, Cancer Res, 66, 6361, 10.1158/0008-5472.CAN-06-0080 · DOI
  18. Maslak, 2006, Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome, Leukemia, 20, 212, 10.1038/sj.leu.2404050 · DOI
  19. Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia, Blood, 108, 3271, 10.1182/blood-2006-03-009142 · DOI
  20. Kirschbaum, 2009, Vorinostat in combination with decitabine for the treatment of relapsed or newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS): a phase I, dose-escalation study [abstract], Blood, 114, 10.1182/blood.V114.22.2089.2089 · DOI
  21. Quintás-Cardama, 2012, Very high rates of clinical and cytogenetic response with the combination of the histone deacetylase inhibitor pracinostat (SB939) and 5-azacitidine in high-risk myelodysplastic syndrome [abstract], Blood, 120, 10.1182/blood.V120.21.3821.3821 · DOI
  22. Prebet, 2014, Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905, J Clin Oncol, 32, 1242, 10.1200/JCO.2013.50.3102 · DOI
  23. Sekeres, 2017, Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117, J Clin Oncol, 35, 2745, 10.1200/JCO.2015.66.2510 · DOI · Paper page
  24. Abaza, 2017, Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies, Cancer, 123, 4851, 10.1002/cncr.30949 · DOI
  25. Novotny-Diermayr, 2010, SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer, Mol Cancer Ther, 9, 642, 10.1158/1535-7163.MCT-09-0689 · DOI
  26. Novotny-Diermayr, 2011, Pharmacodynamic evaluation of the target efficacy of SB939, an oral HDAC inhibitor with selectivity for tumor tissue, Mol Cancer Ther, 10, 1207, 10.1158/1535-7163.MCT-11-0044 · DOI
  27. Wang, 2011, Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile, J Med Chem, 54, 4694, 10.1021/jm2003552 · DOI
  28. Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood, 96, 4075, 10.1182/blood.V96.13.4075 · DOI
  29. Silverman, 2006, Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B, J Clin Oncol, 24, 3895, 10.1200/JCO.2005.05.4346 · DOI
  30. Al-Ali, 2012, Azacitidine in patients with acute myeloid leukemia medically unfit for or resistant to chemotherapy: a multicenter phase I/II study, Leuk Lymphoma, 53, 110, 10.3109/10428194.2011.606382 · DOI
  31. Pleyer, 2014, Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group, Ann Hematol, 93, 1825, 10.1007/s00277-014-2126-9 · DOI
  32. Cheson, 2003, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, J Clin Oncol, 21, 4642, 10.1200/JCO.2003.04.036 · DOI
  33. Jongen-Lavrencic, 2018, Molecular minimal residual disease in acute myeloid leukemia, N Engl J Med, 378, 1189, 10.1056/NEJMoa1716863 · DOI
  34. Morita, 2018, Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia, J Clin Oncol, 36, 1788, 10.1200/JCO.2017.77.6757 · DOI
  35. Kantarjian, 2006, Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome, Cancer, 106, 1090, 10.1002/cncr.21723 · DOI
  36. Corces-Zimmerman, 2014, Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission, Proc Natl Acad Sci USA, 111, 2548, 10.1073/pnas.1324297111 · DOI · Paper page
  37. Garcia-Manero, 2017, Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes, Cancer, 123, 994, 10.1002/cncr.30533 · DOI · Paper page

Cited by

See all 78

Metadata

Authors
Garcia-Manero, G., Abaza, Y., Takahashi, K., Medeiros, B. C., Arellano, M., Khaled, S. K., Patnaik, M., Odenike, O., Sayar, H., Tummala, M., Patel, P., Maness-Harris, L., Stuart, R., Traer, E., Karamlou, K., Yacoub, A., Ghalie, R., Giorgino, R., & Atallah, E.
Venue
Blood Advances
Publisher
American Society of Hematology
Published
2019-02-13
Volume
3
Issue
4
Pages
508-518
ISSN
  • 2473-9529
  • 2473-9537
DOI
10.1182/bloodadvances.2018027409
Cited by
78
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review